Back to top

Image: Bigstock

FDA EUA for Coronavirus Tests Boosts MedTech: 3 Stocks in Focus (Revised)

Read MoreHide Full Article

The coronavirus pandemic continues to weigh on the global stock market.Most U.S. companies across industry domains have slashed their first-quarter guidance owing to expectations of revenue losses.Last month, a study by The Guardian estimated that the outbreak might cost the global economy more than $1 trillion.

FDA Steps Up Efforts

Amid this crisis, the FDA has been continuously stepping up its efforts to bring swift and efficient solutions, which can bring respite to patients and healthcare professionals. On Feb 29, the FDA decided to allow certain certified laboratories to urgently begin developing validated coronavirus diagnostics, subject to the condition that the test is submitted for review within 15 days to the federal agency.

Several key biotech and molecular diagnostic players received FDA’s Emergency Use Authorization (EUA) for COVID-19 tests, which they have been rigorously working on developing and launching commercially lately. Through this, the federal regulatory body expedited the approval procedure for the companies’ tests so that diagnostic professionals could begin conducting the same in any state health laboratory immediately.

Recently Mesa Biotech attained FDA’s EUA for its point-of-care COVID-19 test.This comes right on the heels of diagnostics firm Cepheid attaining the same for its rapid molecular diagnostic test, Xpert Xpress SARS-CoV-2.

Quest Diagnostics (DGX - Free Report) had launched a COVID-19 test service on Mar 9, 2020. This test too attained the FDA’s EUA on Mar 17. As of Mar 23, the company performed and reported results for 106,000 COVID-19 tests.

Hologic (HOLX - Free Report) too announced the receipt of the FDA’s EUA for its latest molecular diagnostic test, Panther Fusion SARS-CoV-2 assay, a real-time polymerase chain reaction (RT-PCR) in-vitro diagnostic test, which is intended to be used for the qualitative detection of RNA from the SARS-CoV-2.

3 Stocks to Focus On

The following Zacks Rank #3 (Hold) companies have already attained EUA for their newly developed coronavirus tests, banking on which the stocks are currently outperforming the broader industries they belong to. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here

PerkinElmer (PKI - Free Report) : This Zacks Rank #3 company recently attained EUA from the FDA for its New Coronavirus RT-PCR test. Clinical laboratories that are certified under Clinical Laboratory Improvement Amendments (CLIA) can start utilizing this test kit to detect SARS-CoV-2 (virus causing COVID-19) immediately.Notably, this test is marketed as an in-vitro diagnostic (IVD) device on basis of fulfilling the requirements of European In Vitro Diagnostic Directive (IVDD). The test kit is now available in more than 30 countries worldwide.

In the past six months, the company’s shares have outperformed the industry.The stock has lost 10.4% compared with the industry’s 12.7% decline.

Abbott Laboratories (ABT - Free Report) :This Zacks Rank #3 global major recently announced the receipt of the EUA from the FDA to use its molecular test RealTime SARS-CoV-2 EUA to detect COVID-19. Notably, the test will run on the company’s m2000 RealTime System. Abbott is on track to ship 150,000 RealTime SARS-CoV-2 EUA tests to existing customers in the United States. At the same time, the company will coordinate with health systems and government authorities to supply additional m2000 systems per requirement.

In the past year, the company’s shares have outperformed the industry.The stock has lost 6.4% compared with the industry’s 15.5% decline.

Thermo Fisher (TMO - Free Report) : This Zacks Rank #3 global manufacturer of scientific instruments recently attained EUA from the FDA for its diagnostic test to be used immediately by CLIA high-complexity laboratories in the United States. The test has been developed for the detection of nucleic acid exclusively from SARS-CoV-2. The authorized test utilizes the Applied Biosystems TaqPath Assay technology and has been developed to deliver patient outcomes within four hours of a sample reaching a laboratory. The estimated time-to-result constitutes of time for sample preparation and instrument analysis. The EUA test is optimized for use on the company's Applied Biosystems 7500 Fast Dx Real-time PCR instrument. The instrument is covered under the EUA and is already utilized in clinical laboratories across the globe.

In the past year, the company’s shares have outperformed the industry.The stock has lost 0.6% compared with  the industry’s 15.1% decline.

 

(We are reissuing this article to correct a mistake. The original article, issued on March 27, 2020, should no longer be relied upon.)